Skip to main content

Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay

Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.